Safety and Immunogenicity of Covid-19 Vaccines in Patients with Cancer: A Network Meta-Analysis of 11357 Patients
DOI:
https://doi.org/10.5195/ijms.2022.1839Keywords:
COVID-19, Cancer, Vaccine, Network Meta-analysisAbstract
Background: The COVID-19 pandemic has had a devastating impact worldwide, especially among patients with cancer as they are more likely to experience severe infection and worse outcomes than the general population. Cancer patients have been excluded from the confirmatory clinical trials which create a gap in the clinical data addressing the effectiveness and safety of the vaccines in this group of immunocompromised patients. Therefore, this study aims to evaluate the findings of all relevant individual studies about the serological response to COVID-19 vaccines in cancer patients compared with healthy participants.
Method: We searched for published relevant studies in the following electronic databases: PubMed, Scopus, Cochrane Library, and Web of Science from inception until 1st August 2022. Data were extracted from eligible studies and pooled as a risk ratio or mean difference (MD) in the network meta-analysis model with the corresponding 95% confidence interval. We used the random effect model in case of significant heterogeneity, otherwise, a fixed-effect model was used. We analyzed the data using R version 4 for windows.
Results: We included 42 studies (3 randomized controlled trials and 39 observational) with a total of 11357 patients in this network meta-analysis. The pooled effect estimates showed that healthy participants were better than cancer patients with solid and hematological tumors in seroconversion [(RR = 0.81; 95% CI 0.75, 0.87; P < 0.00001)), (RR = 0.61; 95% CI 0.54, 0.69; P < 0.00001); respectively]. However, the pooled effect estimates showed that there was no difference between healthy participants and Cancer patients with solid tumors in terms of Covid-19 antibody titer, T-cell response, and adverse events (MD = -160.82; 95% CI -3089.28, 2768.18; P = 0.91), (RR = 1.10; 95% CI 0.69,1.75; P = 0.69), (RR = 1.06; 95% CI 0.88,1.27; P= 0.54), respectively. Additionally, there was no significant difference between the different types of vaccines in terms of COVID-19 antibody titer.
Conclusion: In conclusion, the current evidence demonstrated that the seroconversion rate in healthy participants was higher than in patients with solid and hematological cancers. Nevertheless, our network meta-analysis revealed no significant difference between the two groups in terms of Covid-19 antibody titer, T-cell response, and adverse events. Accordingly, the present evidence is not sufficient to confirm the safety and efficacy of covid-19 vaccine among cancer patients. Therefore, further studies are recommended.
Metrics
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Khaled Albakri, Abdulrhman Khaity, Rawan Mustafa Hamamreh , Balqees Mohammad Hanaqtah, Nora AlKhateeb, Eman E. Alshial, Mohammed Tarek
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org
